Discover Allurion Technologies' Q1 2025 earnings highlights, featuring a revamped B2B2C strategy, FDA progress, improved margins, and future growth plans.

The unintentional theme of today’s issue is the struggle for control over how we implement AI in the U.S. On one side, where ...

The U.S. Digital Therapeutics Market encompasses software-driven solutions designed to prevent, manage, and treat medical conditions and diseases through evidence-based, clinically validated digital ...

"By combining internal, pre-clinical experimental data, with real-world data from Tempus on its AI-powered platform, we can profoundly deepen our understanding of cancer biology and accelerate our ...

Tech companies are focusing on AI products over research, say industry experts, who are sounding the alarm about safety.

There could be an upside to incorporating AI for the FDA. Using AI to assist in final drug reviews would "represent a chance ...

VUNO, a leading South Korean medical AI company, announced today that its flagship AI-powered cardiac arrest risk management system VUNO Med®-DeepCARS®(DeepCARS) has received CE MDR (Medical Device ...

VUNO Med®-DeepCARS® (DeepCARS) is an AI-powered medical device designed to monitor the risk of in-hospital cardiac arrest within the next 24 hours. It analyzes patients' vital signs-including blood ...

Experts have cautioned against adopting the technology too quickly for clinical purposes. The first meeting of FDA’s Digital ...

The US Food and Drug Administration (FDA) has set an "aggressive" timeline to implement generative artificial intelligence ...

Donald Trump has promised to create a pro-AI environment, but even tech companies are frustrated by federal cuts that hamper regulatory processes. Paul Webster reports.

The Food and Drug Administration on Thursday announced an aggressive agency-wide Artificial intelligence adoption timeline ...